Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases.
The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercialising RNAi therapeutics. This platform is protected by Silence’s strong intellectual property portfolio.
UPDATE: Silence Therapeutics unveils tie-up with one of the world's leading drugs companies
Adds broker comments....
Silence Therapeutics (LON:SLN) has struck a deal with one of the world’s leading global pharmaceuticals companies, which will further its research into short interfering RNA sequences, known as siRNAs.
The two will look at the intravenous use of Silence’s DACC technology to deliver siRNAs to the lung.
The name of the drugs giant involved was not revealed. The biotechnology group already has tie-ups with Pfizer (NYSE:PFE), Novartis (VTX:NOVN) and AstraZeneca (LON:AZN).
At the very leading edge of drug development, siRNAs are double-stranded molecules that silence certain genes. They are being developed to be used in targeting multiple disease types, including cancer.
Newly appointed chief executive Thomas Christély said of this latest alliance: "We are delighted to be collaborating with another of the world's largest pharmaceutical companies for the use of our delivery systems to deliver their selected siRNAs.
“As we have stated, Silence is now significantly increasing its resource in business development, and we are delighted to be announcing another partnership.
“We believe that Silence's proprietary DACC delivery system offers the potential to selectively deliver siRNAs and other oligonucleotides to pulmonary vascular endothelium, and we look forward to working closely with our partner on this project.
“Functional delivery into target cells is one of the greatest challenges facing most nucleic acid therapies and Silence remains committed to the development of its DACC and its other proprietary delivery systems, including AtuPLEXtm and DBTC, as it seeks to overcome these challenges."
Analyst Shawn Manning, at broker Singer, said today's announcement was not "entirely unexpected" because of the firm's unique delivery system and the unmet need for a reliable delivery system for siRNA.
"However, the deal further validates Silence’s approach, and although the partnership is likely to be 12-18 months away from generation of a lead candidate, the agreement demonstrates that Silence’s technology platform remains in demand," he said, adding that the broker maintained its positive outlook for the company.